T. Rowe Price Associates
CRSP icon

T. Rowe Price Associates’s CRISPR Therapeutics CRSP Stock Holding History

T. Rowe Price Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5M Buy
105,000
+20,060
+24% +$1.06M ﹤0.01% 1418
2025
Q4 		$4.46M Buy
84,940
+8,405
+11% +$503K ﹤0.01% 1424
2025
Q3 		$4.96M Buy
76,535
+10,168
+15% +$584K ﹤0.01% 1392
2025
Q2 		$3.23M Buy
66,367
+39,004
+143% +$1.51M ﹤0.01% 1443
2025
Q1 		$932K Buy
27,363
+2,800
+11% +$119K ﹤0.01% 1994
2024
Q4 		$967K Buy
24,563
+800
+3% +$37.8K ﹤0.01% 1983
2024
Q3 		$1.12M Sell
23,763
-396,932
-94% -$20.1M ﹤0.01% 1932
2024
Q2 		$22.7M Sell
420,695
-179,539
-30% -$10.4M ﹤0.01% 928
2024
Q1 		$40.9M Sell
600,234
-264,112
-31% -$18.9M 0.01% 777
2023
Q4 		$54.1M Sell
864,346
-5,291
-0.6% -$292K 0.01% 689
2023
Q3 		$39.5M Sell
869,637
-12,738
-1% -$658K 0.01% 755
2023
Q2 		$49.5M Sell
882,375
-220,346
-20% -$12.5M 0.01% 707
2023
Q1 		$49.9M Sell
1,102,721
-20,127
-2% -$978K 0.01% 683
2022
Q4 		$45.6M Sell
1,122,848
-64,614
-5% -$3.43M 0.01% 688
2022
Q3 		$77.6M Sell
1,187,462
-1,827,089
-61% -$132M 0.01% 537
2022
Q2 		$183M Buy
3,014,551
+1,848,437
+159% +$109M 0.02% 499
2022
Q1 		$73.2M Buy
1,166,114
+75,301
+7% +$4.73M 0.01% 833
2021
Q4 		$82.7M Sell
1,090,813
-93,916
-8% -$8.2M 0.01% 827
2021
Q3 		$133M Sell
1,184,729
-4,544
-0.4% -$571K 0.01% 677
2021
Q2 		$193M Sell
1,189,273
-109,056
-8% -$13.3M 0.02% 574
2021
Q1 		$158M Sell
1,298,329
-476,107
-27% -$71.9M 0.02% 627
2020
Q4 		$272M Buy
1,774,436
+143,504
+9% +$17M 0.03% 444
2020
Q3 		$136M Buy
1,630,932
+255,605
+19% +$22.7M 0.02% 579
2020
Q2 		$101M Buy
1,375,327
+364,124
+36% +$21.3M 0.01% 638
2020
Q1 		$42.9M Sell
1,011,203
-98,969
-9% -$5.11M 0.01% 830
2019
Q4 		$67.6M Buy
1,110,172
+411,929
+59% +$22.5M 0.01% 794
2019
Q3 		$28.6M Sell
698,243
-40,626
-5% -$1.94M ﹤0.01% 1041
2019
Q2 		$34.8M Buy
738,869
+121,176
+20% +$4.84M ﹤0.01% 1002
2019
Q1 		$22.1M Buy
617,693
+1,845
+0.3% +$63.8K ﹤0.01% 1152
2018
Q4 		$17.6M Buy
615,848
+413,212
+204% +$14.4M ﹤0.01% 1189
2018
Q3 		$8.99M Buy
202,636
+3,061
+2% +$160K ﹤0.01% 1394
2018
Q2 		$11.7M Buy
+199,575
New +$11.4M ﹤0.01% 1319
2017
Q4 		– Sell
-151,510
Closed -$2.71M – 2574
2017
Q3 		$2.71M Buy
+151,510
New +$2.75M ﹤0.01% 1517

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates's CRSP Position: Q1 2026 in Review

T. Rowe Price Associates increased its CRISPR Therapeutics (CRSP) stake by 24% in Q1 2026, buying an estimated $1.06M and bringing the position to 105,000 shares worth $5M. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

T. Rowe Price Associates first reported a position in CRSP in Q3 2017 and has held it in 33 quarters since. The position peaked at $272M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • T. Rowe Price Associates held 105,000 shares of CRISPR Therapeutics worth $5M as of Q1 2026.
  • T. Rowe Price Associates bought 20,060 CRISPR Therapeutics shares in Q1 2026, an estimated $1.06M.
  • CRISPR Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1418 holding.
  • T. Rowe Price Associates first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 33 quarters since.
  • T. Rowe Price Associates's CRISPR Therapeutics position peaked at $272M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.